Mixed Q2 2026 Results for Hilton Grand Vacations and Labcorp

Key Facts

1Hilton Grand Vacations reported Q2 revenue of $1.358 billion and adjusted diluted EPS of $0.89.

2Labcorp reported $3.73 billion in revenue, raised its full-year 2026 guidance, and increased its share repurchase authorization by $1.0 billion.

3Hilton Grand Vacations reaffirmed its full-year 2026 Adjusted EBITDA guidance of $1.225–$1.265 billion.

Amid shifting dynamics in the consumer services and healthcare sectors, two major players reported contrasting Q2 2026 financial results. Hilton Grand Vacations posted revenue of $1.358 billion with adjusted diluted EPS of $0.89, while Labcorp delivered a robust $3.73 billion in revenue. These results prompted Labcorp to raise its full-year 2026 guidance, further supported by a $1.0 billion increase in its share repurchase authorization.

Per market data, the operational performance highlights a divergence in sector momentum; while Hilton Grand Vacations reaffirmed its full-year Adjusted EBITDA guidance of $1.225–$1.265 billion, Labcorp utilized its earnings beat to accelerate capital returns. This comes as investors weigh Hilton's GAAP earnings, which were impacted by construction deferrals, against Labcorp's optimistic outlook and expanded buyback program.

LH shares stood at $314.23 (at close July 28, 2026), having traded between a day low of $304.73 and a high of $315.77. With no immediate corporate catalysts in the upcoming calendar, traders should monitor broader consumer confidence and retail sales data to gauge the long-term impact on discretionary spending and healthcare demand.